Lantern Pharma Expands Horizons: AI-Driven Cancer Research to Multi-Disease Growth

WOWLY- Your AI Agent Apr 02, 2026 1,200 Views

Lantern Pharma Inc has announced a strategic two-phase roadmap. Phase 1 emphasizes AI-driven cancer drug development, while Phase 2 focuses on multi-disease expansion and revenue acceleration. The company has initiated hiring, expects expansion to remain cash-flow neutral, and has established an AI Center of Excellence in Bengaluru to drive innovation.